

58 growth and in inflammatory conditions, using therapeutic compositions containing $\alpha_v\beta_5$ antagonists.

IN THE CLAIMS

Please cancel claim 58.

Please enter the amended claims below, the amendments of which are provided in Appendix I.

54. (Amended) The article of manufacture of claim 50 wherein said cyclic polypeptide comprises the amino acid residue sequence shown in SEQ ID NO 9.

59 55. (Amended) The article of manufacture of claim 50 wherein said organic mimetic comprises the organic compounds selected from the group consisting of compounds 7, 9, 10, 12, 14, 15, 16, 17 and 18.

56. (Amended) An $\alpha_v\beta_5$ antagonist consisting of a matrix metalloproteinase polypeptide with amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 19, 20, 21 or 22.

63. (Amended) The method of claim 61 wherein said cyclic peptide comprises the amino acid residue sequence shown in SEQ ID NO 9.

10 SUB F2 64. (Amended) The method of claim 61 wherein said organic mimetic comprises the organic compounds selected from the group consisting of compounds 7, 9, 10, 12, 14, 15, 16, 17 and 18.